VEGFA and hepatocellular carcinoma: ICIs, in combination or when combined with anti‐VEGF agents, have shown synergistic antitumor effects and better quality of life (QOL) endpoints compared with sorafenib in patients with advanced HCC and CP A.23First‐line atezolizumab plus bevacizumab was proven to be superior to sorafenib (HR 0.58; p < 0.001) in the Phase 3 IMbrave150 trial in patients with advanced HCC and CP A who had not previously received any systemic treatment.16, 68